*/
Casey Randall, Head of DNA at AlphaBiolabs (© AlphaBiolabs)
News comes as demand for prenatal paternity tests surges by 47% versus pre-pandemic levels
Leading legal DNA testing provider AlphaBiolabs has become the first UK testing laboratory to be awarded accreditation for its non-invasive prenatal paternity testing.
The company, which provides a range of legal testing services including DNA, drug and alcohol testing for local authorities and family law professionals, was awarded ISO 17025 accreditation by the UK Accreditation Service (UKAS) following a two-year validation process.
Beginning in 2019, the AlphaBiolabs DNA team undertook an extensive validation project, ensuring that the company’s prenatal paternity testing methods met the highest possible standards for efficacy, as required by UKAS.
The project was then submitted to UKAS, and an external audit was conducted to ensure the company’s DNA analysis met the criteria for ISO 17025 accreditation, an internationally recognised standard for Testing and Calibration Laboratories.
News of the accreditation comes as figures show demand for prenatal paternity tests is on the rise.
As of 2021, the company recorded a 47% increase in prenatal paternity tests versus pre-pandemic levels*
as more people become aware of the benefits of this innovative, risk-free test.
A non-invasive prenatal paternity test can be carried out from as early as seven weeks into pregnancy, making it possible to determine paternity before a baby is born.
An AlphaBiolabs prenatal paternity test is 100% safe for both mother and baby, as it only requires cheek swabs and a blood sample from the mother and cheek swabs from the father. It is possible to identify the unborn baby’s DNA via the mother’s blood sample, as DNA from the foetus is passed into the mother’s bloodstream via the placenta during pregnancy.
If the man in question is the biological father of the child, the man and baby will share DNA markers.
For childcare proceedings, knowing the biological father of a child in early pregnancy carries significant benefits, enabling local authorities to implement plans for safeguarding where a baby may be at risk of serious harm.
It can also help prevent delays to pre-care, care, or supervision proceedings.
Casey Randall, Head of DNA at AlphaBiolabs, said: “To be the first testing laboratory in the UK to secure this accreditation is a fantastic achievement, and testament to the hard work and dedication of our DNA team.
“Establishing paternity before a baby is born can play a fundamental role in court proceedings, especially in cases where the safeguarding of a child is paramount.
“With the addition of UKAS accreditation, our legal clients can be confident that AlphaBiolabs’ prenatal paternity testing is performed to the highest possible standard for fast, accurate results that they can trust.”
AlphaBiolabs is accredited by the Ministry of Justice to carry out parentage tests as directed by the civil courts in England and Wales under Section 20 of the Family Law Reform Act (1969).
For every legal instruction received throughout 2022, AlphaBiolabs is also donating £5 via its Giving Back campaign, supporting four incredible charities that work with vulnerable children and families across the UK.
* Source: AlphaBiolabs DNA testing data, number of prenatal paternity tests performed (2019-2021)
Further information
Please contact AlphaBiolabs on 0333 600 1300 or email: testing@alphabiolabs.com or visit https://www.alphabiolabs.co.uk
Founded in 2004 and headquartered in Warrington, Cheshire, AlphaBiolabs is a leading and award-winning provider of DNA, drug, alcohol, and COVID-19 testing services in the UK. For more information please visit: https://www.alphabiolabs.co.uk
Leading legal DNA testing provider AlphaBiolabs has become the first UK testing laboratory to be awarded accreditation for its non-invasive prenatal paternity testing.
The company, which provides a range of legal testing services including DNA, drug and alcohol testing for local authorities and family law professionals, was awarded ISO 17025 accreditation by the UK Accreditation Service (UKAS) following a two-year validation process.
Beginning in 2019, the AlphaBiolabs DNA team undertook an extensive validation project, ensuring that the company’s prenatal paternity testing methods met the highest possible standards for efficacy, as required by UKAS.
The project was then submitted to UKAS, and an external audit was conducted to ensure the company’s DNA analysis met the criteria for ISO 17025 accreditation, an internationally recognised standard for Testing and Calibration Laboratories.
News of the accreditation comes as figures show demand for prenatal paternity tests is on the rise.
As of 2021, the company recorded a 47% increase in prenatal paternity tests versus pre-pandemic levels*
as more people become aware of the benefits of this innovative, risk-free test.
A non-invasive prenatal paternity test can be carried out from as early as seven weeks into pregnancy, making it possible to determine paternity before a baby is born.
An AlphaBiolabs prenatal paternity test is 100% safe for both mother and baby, as it only requires cheek swabs and a blood sample from the mother and cheek swabs from the father. It is possible to identify the unborn baby’s DNA via the mother’s blood sample, as DNA from the foetus is passed into the mother’s bloodstream via the placenta during pregnancy.
If the man in question is the biological father of the child, the man and baby will share DNA markers.
For childcare proceedings, knowing the biological father of a child in early pregnancy carries significant benefits, enabling local authorities to implement plans for safeguarding where a baby may be at risk of serious harm.
It can also help prevent delays to pre-care, care, or supervision proceedings.
Casey Randall, Head of DNA at AlphaBiolabs, said: “To be the first testing laboratory in the UK to secure this accreditation is a fantastic achievement, and testament to the hard work and dedication of our DNA team.
“Establishing paternity before a baby is born can play a fundamental role in court proceedings, especially in cases where the safeguarding of a child is paramount.
“With the addition of UKAS accreditation, our legal clients can be confident that AlphaBiolabs’ prenatal paternity testing is performed to the highest possible standard for fast, accurate results that they can trust.”
AlphaBiolabs is accredited by the Ministry of Justice to carry out parentage tests as directed by the civil courts in England and Wales under Section 20 of the Family Law Reform Act (1969).
For every legal instruction received throughout 2022, AlphaBiolabs is also donating £5 via its Giving Back campaign, supporting four incredible charities that work with vulnerable children and families across the UK.
* Source: AlphaBiolabs DNA testing data, number of prenatal paternity tests performed (2019-2021)
Further information
Please contact AlphaBiolabs on 0333 600 1300 or email: testing@alphabiolabs.com or visit https://www.alphabiolabs.co.uk
News comes as demand for prenatal paternity tests surges by 47% versus pre-pandemic levels
The Chair of the Bar reports back
Susie Griffin on the admin that keeps barristers from billable work
Clement Cowley, Partner at The Penny Group, explains how global events can influence the performance of pensions and ISAs, and why taking a long-term approach to investing is often the most effective strategy
Mário Barroso, Head of R&D and Method Development at AlphaBiolabs, discusses what family law professionals need to know about hallucinogens, from the main hallucinogenic drugs encountered in family proceedings, to their effects and the testing options available
Harmony Christian Ministries is the latest charity to benefit from a £500 donation from AlphaBiolabs via the company’s Giving Back initiative
By David Green
At the start of her term, Chair of the Bar 2026 Kirsty Brimelow KC set out a series of priorities for the year ahead. One of those priorities was children in the justice system
As the world becomes more digital, Barbara Vinagre Mota examines international research into the mental health consequences of judges’ exposure to graphic and immersive evidence, highlighting the importance of support systems
In an era of patient-centred care and growing concern over misconduct in medical settings, why do women still lack the right to choose women consultants for examination and treatment? Charles Davey investigates
Reviewed by Daniel Barnett
James McNeill Whistler at Tate Britain until 27 September Rothko in Florence at Palazzo Strozzi until 23 August Reviewed by Stephen Cragg KC
